Published on 15 Apr 2024 on Zacks via Yahoo Finance
Roche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
Roche Holding AG RHHBY announced that the late-stage study evaluating its marketed drug, Columvi (glofitamab), in combination with gemcitabine and oxaliplatin (GemOx), for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) met its primary endpoint of overall survival.
Columvi is Roche’s fixed-duration and CD20xCD3 T-cell engaging bispecific antibody. It is currently approved as a monotherapy by the FDA to treat people with R/R DLBCL after two or more lines of systemic therapy on an accelerated basis. The drug has also received conditional marketing authorization in the EU for the same indication.